{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:49:33Z","timestamp":1793332173260,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple sclerosis (MS) affects 2.9 million people. Traditional classification of MS into distinct subtypes poorly reflects its pathobiology and has limited value for prognosticating disease evolution and treatment response, thereby hampering drug discovery. Here we report a data-driven classification of MS disease evolution by analyzing a large clinical trial database (approximately 8,000 patients, 118,000 patient visits and more than 35,000 magnetic resonance imaging scans) using probabilistic machine learning. Four dimensions define MS disease states: physical disability, brain damage, relapse and subclinical disease activity. Early\/mild\/evolving (EME) MS and advanced MS represent two poles of a disease severity spectrum. Patients with EME MS show limited clinical impairment and minor brain damage. Transitions to advanced MS occur via brain damage accumulation through inflammatory states, with or without accompanying symptoms. Advanced MS is characterized by moderate to high disability levels, radiological disease burden and risk of disease progression independent of relapses, with little probability of returning to earlier MS states. We validated these results in an independent clinical trial database and a real-world cohort, totaling more than 4,000 patients with MS. Our findings support viewing MS as a disease continuum. We propose a streamlined disease classification to offer a unifying understanding of the disease, improve patient management and enhance drug discovery efficiency and precision.<\/jats:p>","DOI":"10.1038\/s41591-025-03901-6","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T09:03:01Z","timestamp":1755680581000},"page":"3414-3424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["AI-driven reclassification of multiple sclerosis progression"],"prefix":"10.1038","volume":"31","author":[{"given":"Habib","family":"Ganjgahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5690-8710","authenticated-orcid":false,"given":"Dieter A.","family":"H\u00e4ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-7985","authenticated-orcid":false,"given":"Piet","family":"Aarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-0953","authenticated-orcid":false,"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5157-1087","authenticated-orcid":false,"given":"Stephen","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3384-3704","authenticated-orcid":false,"given":"Elizabeth","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5214-2858","authenticated-orcid":false,"given":"Laura","family":"Gaetano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5553-9252","authenticated-orcid":false,"given":"Stefan P.","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-5103","authenticated-orcid":false,"given":"Thomas E.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-8496","authenticated-orcid":false,"given":"Alan J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-0475","authenticated-orcid":false,"given":"Fred D.","family":"Lublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5509","authenticated-orcid":false,"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0106","authenticated-orcid":false,"given":"Douglas L.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2334-6883","authenticated-orcid":false,"given":"Robert A.","family":"Bermel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-3432","authenticated-orcid":false,"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6667-4943","authenticated-orcid":false,"given":"Chris C.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"3901_CR1","unstructured":"MS International Federation. Atlas of MS. https:\/\/www.atlasofms.org"},{"key":"3901_CR2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult. Scler. 26, 1816\u20131821 (2020).","journal-title":"Mult. Scler."},{"key":"3901_CR3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin, F. D. & Reingold, S. C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46, 907\u2013911 (1996).","journal-title":"Neurology"},{"key":"3901_CR4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278\u2013286 (2014).","journal-title":"Neurology"},{"key":"3901_CR5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","volume":"15","author":"D Rotstein","year":"2019","unstructured":"Rotstein, D. & Montalban, X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat. Rev. Neurol. 15, 287\u2013300 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"3901_CR6","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1177\/13524585221094944","volume":"28","author":"M Capanna","year":"2022","unstructured":"Capanna, M., Signori, A. & Sormani, M. P. Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials. Mult. Scler. 28, 1744\u20131751 (2022).","journal-title":"Mult. Scler."},{"key":"3901_CR7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree, B. A. C. et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann. Neurol. 85, 653\u2013666 (2019).","journal-title":"Ann. Neurol."},{"key":"3901_CR8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/1352458517709619","volume":"24","author":"L Kappos","year":"2018","unstructured":"Kappos, L. et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult. Scler. 24, 963\u2013973 (2018).","journal-title":"Mult. Scler."},{"key":"3901_CR9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos, L. et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 77, 1132\u20131140 (2020).","journal-title":"JAMA Neurol."},{"key":"3901_CR10","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin, F. D. et al. How patients with multiple sclerosis acquire disability. Brain 145, 3147\u20133161 (2022).","journal-title":"Brain"},{"key":"3901_CR11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"C Tur","year":"2023","unstructured":"Tur, C. et al. Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 80, 151\u2013160 (2023).","journal-title":"JAMA Neurol."},{"key":"3901_CR12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","volume":"8","author":"H Lassmann","year":"2012","unstructured":"Lassmann, H., van Horssen, J. & Mahad, D. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 8, 647\u2013656 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"3901_CR13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41582-021-00581-x","volume":"18","author":"HYF Yong","year":"2022","unstructured":"Yong, H. Y. F. & Yong, V. W. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat. Rev. Neurol. 18, 40\u201355 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"3901_CR14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaneurol.2020.4689","volume":"78","author":"M Filippi","year":"2021","unstructured":"Filippi, M. et al. Diagnosis of progressive multiple sclerosis from the imaging perspective: a review. JAMA Neurol. 78, 351\u2013364 (2021).","journal-title":"JAMA Neurol."},{"key":"3901_CR15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann, T. et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 22, 78\u201388 (2023).","journal-title":"Lancet Neurol."},{"key":"3901_CR16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He, A. et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 19, 307\u2013316 (2020).","journal-title":"Lancet Neurol."},{"key":"3901_CR17","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.0000000000009636","volume":"94","author":"FD Lublin","year":"2020","unstructured":"Lublin, F. D., Coetzee, T., Cohen, J. A., Marrie, R. A. & Thompson, A. J. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology 94, 1088\u20131092 (2020).","journal-title":"Neurology"},{"key":"3901_CR18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamaneurol.2022.4156","volume":"80","author":"C Granziera","year":"2023","unstructured":"Granziera, C., Derfuss, T. & Kappos, L. Time to change the current clinical classification of multiple sclerosis? JAMA Neurol. 80, 128\u2013130 (2023).","journal-title":"JAMA Neurol."},{"key":"3901_CR19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/13524585231196786","volume":"29","author":"AJ Thompson","year":"2023","unstructured":"Thompson, A. J. et al. Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community. Mult. Scler. 29, 1363\u20131372 (2023).","journal-title":"Mult. Scler."},{"key":"3901_CR20","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1177\/1352458520988637","volume":"27","author":"F Dahlke","year":"2021","unstructured":"Dahlke, F. et al. Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): age is a key contributor to presentation. Mult. Scler. 27, 2062\u20132076 (2021).","journal-title":"Mult. Scler."},{"key":"3901_CR21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3901_CR22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376, 209\u2013220 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3901_CR23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fneur.2020.00632","volume":"11","author":"EM Mowry","year":"2020","unstructured":"Mowry, E. M. et al. Harnessing real-world data to inform decision-making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). Front. Neurol. 11, 632 (2020).","journal-title":"Front. Neurol."},{"key":"3901_CR24","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1177\/13524585231205973","volume":"29","author":"FD Lublin","year":"2023","unstructured":"Lublin, F. D. Worsening MS\u2014a reappraisal of how we characterize the MS disease course. Mult. Scler. 29, 1699\u20131700 (2023).","journal-title":"Mult. Scler."},{"key":"3901_CR25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker, K. et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66, 460\u2013471 (2009).","journal-title":"Ann. Neurol."},{"key":"3901_CR26","first-page":"679","volume":"22","author":"JS Wolinsky","year":"2016","unstructured":"Wolinsky, J. S. et al. Fingolimod effect on disability progression in primary progressive multiple sclerosis patients with inflammatory activity: a post-hoc subgroup analysis of the INFORMS study. Mult. Scler. 22, 679\u2013680 (2016).","journal-title":"Mult. Scler."},{"key":"3901_CR27","volume":"12","author":"A Eshaghi","year":"2021","unstructured":"Eshaghi, A. et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat. Commun. 12, 2078 (2021).","journal-title":"Nat. Commun."},{"key":"3901_CR28","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/13524585241275471","volume":"30","author":"A Ocampo","year":"2024","unstructured":"Ocampo, A. et al. Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model. Mult. Scler. 30, 1455\u20131467 (2024).","journal-title":"Mult. Scler."},{"key":"3901_CR29","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1352458516659550","volume":"23","author":"MP Sormani","year":"2017","unstructured":"Sormani, M. P. et al. Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Mult. Scler. 23, 656\u2013664 (2017).","journal-title":"Mult. Scler."},{"key":"3901_CR30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/acn3.534","volume":"5","author":"DH Miller","year":"2018","unstructured":"Miller, D. H. et al. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. Ann. Clin. Transl. Neurol. 5, 346\u2013356 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"3901_CR31","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","volume":"79","author":"A Cagol","year":"2022","unstructured":"Cagol, A. et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol. 79, 682\u2013692 (2022).","journal-title":"JAMA Neurol."},{"key":"3901_CR32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1212\/WNL.46.2.373","volume":"46","author":"JW Thorpe","year":"1996","unstructured":"Thorpe, J. W. et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 46, 373\u2013378 (1996).","journal-title":"Neurology"},{"key":"3901_CR33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","volume":"88","author":"J Kuhle","year":"2017","unstructured":"Kuhle, J. et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 88, 826\u2013831 (2017).","journal-title":"Neurology"},{"key":"3901_CR34","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle, J. et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92, e1007\u2013e1015 (2019).","journal-title":"Neurology"},{"key":"3901_CR35","doi-asserted-by":"crossref","unstructured":"van den Bosch, A. et al. Neurofilament light chain levels in multiple sclerosis correlate with lesions containing foamy macrophages and with acute axonal damage. Neurol. Neuroimmunol. Neuroinflamm. 9, e1154 (2022).","DOI":"10.1212\/NXI.0000000000001154"},{"key":"3901_CR36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1212\/WNL.0000000000001281","volume":"84","author":"EW Radue","year":"2015","unstructured":"Radue, E. W. et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology 84, 784\u2013793 (2015).","journal-title":"Neurology"},{"key":"3901_CR37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/13524585241272046","volume":"30","author":"M Petracca","year":"2024","unstructured":"Petracca, M. et al. Brain reserve and timing of clinical onset in multiple sclerosis. Mult. Scler. 30, 1290\u20131295 (2024).","journal-title":"Mult. Scler."},{"key":"3901_CR38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes, M. P. et al. 2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 20, 653\u2013670 (2021).","journal-title":"Lancet Neurol."},{"key":"3901_CR39","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller, J. et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol. 80, 1232\u20131245 (2023).","journal-title":"JAMA Neurol."},{"key":"3901_CR40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/WCO.0b013e328346056f","volume":"24","author":"C Stadelmann","year":"2011","unstructured":"Stadelmann, C. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr. Opin. Neurol. 24, 224\u2013229 (2011).","journal-title":"Curr. Opin. Neurol."},{"key":"3901_CR41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/B978-0-444-52001-2.00042-X","volume":"122","author":"BA Cree","year":"2014","unstructured":"Cree, B. A. Genetics of primary progressive multiple sclerosis. Handb. Clin. Neurol. 122, 211\u2013230 (2014).","journal-title":"Handb. Clin. Neurol."},{"key":"3901_CR42","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/brain\/awp070","volume":"132","author":"JM Frischer","year":"2009","unstructured":"Frischer, J. M. et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175\u20131189 (2009).","journal-title":"Brain"},{"key":"3901_CR43","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1177\/1352458514531084","volume":"20","author":"J Kuchling","year":"2014","unstructured":"Kuchling, J. et al. Identical lesion morphology in primary progressive and relapsing-remitting MS\u2014an ultrahigh field MRI study. Mult. Scler. 20, 1866\u20131871 (2014).","journal-title":"Mult. Scler."},{"key":"3901_CR44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-016-1653-y","volume":"133","author":"T Kuhlmann","year":"2017","unstructured":"Kuhlmann, T. et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 133, 13\u201324 (2017).","journal-title":"Acta Neuropathol."},{"key":"3901_CR45","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1177\/1352458517729455","volume":"23","author":"H Lassmann","year":"2017","unstructured":"Lassmann, H. Targets of therapy in progressive MS. Mult. Scler. 23, 1593\u20131599 (2017).","journal-title":"Mult. Scler."},{"key":"3901_CR46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","volume":"135","author":"S Luchetti","year":"2018","unstructured":"Luchetti, S. et al. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. 135, 511\u2013528 (2018).","journal-title":"Acta Neuropathol."},{"key":"3901_CR47","unstructured":"Montalban, X. 2024 revisions of the McDonald criteria. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark. https:\/\/ectrims.eu\/mcdonald-diagnostic-criteria (2024)."},{"key":"3901_CR48","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0016","volume":"12","author":"IA Samjoo","year":"2023","unstructured":"Samjoo, I. A. et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J. Comp. Eff. Res. 12, e230016 (2023).","journal-title":"J. Comp. Eff. Res."},{"key":"3901_CR49","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2022.103006","volume":"34","author":"M Bussas","year":"2022","unstructured":"Bussas, M. et al. Multiple sclerosis lesions and atrophy in the spinal cord: distribution across vertebral levels and correlation with disability. Neuroimage Clin. 34, 103006 (2022).","journal-title":"Neuroimage Clin."},{"key":"3901_CR50","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1007\/s00415-023-11829-5","volume":"270","author":"S Ruggieri","year":"2023","unstructured":"Ruggieri, S. et al. The added value of spinal cord lesions to disability accrual in multiple sclerosis. J. Neurol. 270, 4995\u20135003 (2023).","journal-title":"J. Neurol."},{"key":"3901_CR51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/jnnp-2022-330613","volume":"94","author":"J Sastre-Garriga","year":"2023","unstructured":"Sastre-Garriga, J. et al. Spinal cord reserve in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 94, 502\u2013510 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"3901_CR52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/brain\/awy352","volume":"142","author":"D Eden","year":"2019","unstructured":"Eden, D. et al. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. Brain 142, 633\u2013646 (2019).","journal-title":"Brain"},{"key":"3901_CR53","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1148\/radiol.2020200430","volume":"296","author":"R Bonacchi","year":"2020","unstructured":"Bonacchi, R. et al. Clinical relevance of multiparametric MRI assessment of cervical cord damage in multiple sclerosis. Radiology 296, 605\u2013615 (2020).","journal-title":"Radiology"},{"key":"3901_CR54","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ana.26281","volume":"91","author":"A Bischof","year":"2022","unstructured":"Bischof, A. et al. Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. Ann. Neurol. 91, 268\u2013281 (2022).","journal-title":"Ann. Neurol."},{"key":"3901_CR55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00415-025-13068-2","volume":"272","author":"J Hong","year":"2025","unstructured":"Hong, J. et al. Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up. J. Neurol. 272, 316 (2025).","journal-title":"J. Neurol."},{"key":"3901_CR56","doi-asserted-by":"crossref","first-page":"106211","DOI":"10.1016\/j.compbiomed.2022.106211","volume":"151","author":"DJ Delbarre","year":"2022","unstructured":"Delbarre, D. J. et al. Application of a convolutional neural network to the quality control of MRI defacing. Comput. Biol. Med. 151, 106211 (2022).","journal-title":"Comput. Biol. Med."},{"key":"3901_CR57","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-021-01409-4","volume":"21","author":"AM Mallon","year":"2021","unstructured":"Mallon, A. M. et al. Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis. BMC Med. Res. Methodol. 21, 250 (2021).","journal-title":"BMC Med. Res. Methodol."},{"key":"3901_CR58","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444\u20131452 (1983).","journal-title":"Neurology"},{"key":"3901_CR59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41582-020-00448-7","volume":"17","author":"M D\u2019Souza","year":"2021","unstructured":"D\u2019Souza, M., Papadopoulou, A., Girardey, C. & Kappos, L. Standardization and digitization of clinical data in multiple sclerosis. Nat. Rev. Neurol. 17, 119\u2013125 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"3901_CR60","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/WNL.58.8.1294","volume":"58","author":"SR Schwid","year":"2002","unstructured":"Schwid, S. R., Goodman, A. D., McDermott, M. P., Bever, C. F. & Cook, S. D. Quantitative functional measures in MS: what is a reliable change. Neurology 58, 1294\u20131296 (2002).","journal-title":"Neurology"},{"key":"3901_CR61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.acn.2005.07.006","volume":"21","author":"TN Tombaugh","year":"2006","unstructured":"Tombaugh, T. N. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Arch. Clin. Neuropsychol. 21, 53\u201376 (2006).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"3901_CR62","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121\u2013127 (2001).","journal-title":"Ann. Neurol."},{"key":"3901_CR63","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nimg.2002.1040","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith, S. M. et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17, 479\u2013489 (2002).","journal-title":"Neuroimage"},{"key":"3901_CR64","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00004728-200105000-00022","volume":"25","author":"SM Smith","year":"2001","unstructured":"Smith, S. M., De Stefano, N., Jenkinson, M. & Matthews, P. M. Normalized accurate measurement of longitudinal brain change. J. Comput. Assist. Tomogr. 25, 466\u2013475 (2001).","journal-title":"J. Comput. Assist. Tomogr."},{"key":"3901_CR65","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1080\/01621459.2015.1100620","volume":"111","author":"V Ro\u010dkov\u00e1","year":"2016","unstructured":"Ro\u010dkov\u00e1, V. & George, E. I. Fast Bayesian factor analysis via automatic rotations to sparsity. J. Am. Stat. Assoc. 111, 1608\u20131622 (2016).","journal-title":"J. Am. Stat. Assoc."},{"key":"3901_CR66","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11222-014-9500-2","volume":"26","author":"G Malsiner-Walli","year":"2016","unstructured":"Malsiner-Walli, G., Fr\u00fchwirth-Schnatter, S. & Gr\u00fcn, B. Model-based clustering based on sparse finite Gaussian mixtures. Stat. Comput. 26, 303\u2013324 (2016).","journal-title":"Stat. Comput."},{"key":"3901_CR67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1109\/TIT.1967.1054010","volume":"13","author":"A Viterbi","year":"1967","unstructured":"Viterbi, A. Error bounds for convolutional codes and an asymptotically optimum decoding algorithm. IEEE Trans. Inf. Theory 13, 260\u2013269 (1967).","journal-title":"IEEE Trans. Inf. Theory"},{"key":"3901_CR68","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/sim.6893","volume":"35","author":"RA Sparapani","year":"2016","unstructured":"Sparapani, R. A., Logan, B. R., McCulloch, R. E. & Laud, P. W. Nonparametric survival analysis using Bayesian Additive Regression Trees (BART). Stat. Med. 35, 2741\u20132753 (2016).","journal-title":"Stat. Med."},{"key":"3901_CR69","unstructured":"Jackson, C. Multi-state modelling with R: the msm package. https:\/\/cran.r-project.org\/web\/packages\/msm\/index.html (2007)."},{"key":"3901_CR70","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.53.8.1698","volume":"53","author":"RA Rudick","year":"1999","unstructured":"Rudick, R. A., Fisher, E., Lee, J. C., Simon, J. & Jacobs, L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53, 1698\u20131704 (1999).","journal-title":"Neurology"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03901-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03901-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03901-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T14:02:58Z","timestamp":1760623378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03901-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3901"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03901-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.J.T. receives fees from being Co-Chair, UCL-Eisai Steering Committee drug discovery collaboration; Member, National Multiple Sclerosis Society (NMSS) Research Programs Advisory Committee; Clinical Trials Committee, Progressive MS Alliance; Board Member, European Charcot Foundation; Editor in Chief,\n                      Multiple Sclerosis\n                      journal; and Editorial Board Member,\n                      Lancet Neurology\n                      . He receives no fees from being Chair (Scientific Ambassadors), \u2018Stop MS\u2019 Appeal Board, UK MS Society; research & academic counsellor, Fundaci\u00f3 Privada Cemcat; and Ambassador, European Brain Council. A.J.T. additionally holds a patent for the MSIS-29 Impact Scale. X.M. has received speaking honoraria and travel expenses for participation in scientific meetings and has been a steering committee member of clinical trials or has participated in advisory boards of clinical trials in the past years with AbbVie, Actelion, Alexion, Biogen, Bristol Myers Squibb\/Celgene, EMD Serono, Genzyme, F. Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, MedDay Pharmaceuticals, Merck, Mylan, NervGen, Novartis, Sandoz, Sanofi-Genzyme, Teva, TG Therapeutics, EXCEMED, the MS International Federation and the NMSS. F.D.L. reports as sources of funding for research: Novartis, Actelion, Biogen, Sanofi, NMSS, National Institutes of Health and Brainstorm Cell Therapeutics; consulting agreements\/advisory boards\/data and safety monitoring board: Biogen, EMD Serono, Novartis, Teva, Actelion\/Janssen, Sanofi\/Genzyme, Acorda, Roche\/ Genentech, MedImmune\/Viela Bio, Receptos\/Celgene\/Bristol Myers Squibb, TG Therapeutics, MedDay Pharmaceuticals, Atara Biotherapeutics, Mapi Pharma, Apitope, Orion Biotechnology, Brainstorm Cell Therapeutics, Jazz Pharmaceuticals, GW Pharma, Mylan, Immunic, Population Council, Avotres, Neurogene, Banner Life Sciences, LabCorp, Entelexo Biotherapeutics and NeuraLight; stock options: Avotres and NeuraLight; and speaker: Sanofi (non-promotional). L.K.\u2019s institution (University Hospital Basel) has received the following exclusively for research support: steering committee, advisory board and\/or consultancy fees (Biogen, EMD Serono Research and Development, Genentech, Janssen, Novartis, Clene Nanomedicine, Bayer, Bristol Myers Squibb, Celltrion, Eli Lilly (Suisse) SA, EMD Serono Research and Development, Galapagos NV, Kiniksa Pharmaceuticals, Merck Healthcare AG, Minoryx and Santhera, Neurostatus UHB AG, Roche, Sanofi, Santhera Pharmaceuticals, Shionogi BV, Wellmera AG and Zai Lab); speaker fees (Bristol Myers Squibb, Janssen, Novartis, Roche and Sanofi); grants (European Union, Innosuisse, Merck Healthcare AG, Novartis and Roche); and testimony (Df-mp Mplina & Pohlman). D.L.A. reports consulting fees from Biogen, Biohaven, Bristol Myers Squibb, Eli Lilly, EMD Serono, Find Therapeutics, Frequency Therapeutics, GlaxoSmithKline, Idorsia Pharmaceuticals, Kiniksa Pharmaceuticals, Merck, Novartis, Race to Erase MS, Roche, Sanofi-Aventis, Shionogi and Xfacto Communications as well as an equity interest in NeuroRx. R.A.B. has served as a consultant for AstraZeneca, Biogen, EMD Serono, Genzyme, Genentech, Novartis and VielaBio. He also receives research support from Biogen, Genentech and Novartis. H.W. has received honoraria for being a member of scientific advisory boards for Biogen, Evgen, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG and Sanofi-Aventis as well as speaker honoraria and travel support from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche, Gemeinn\u00fctzige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Genzyme, Teva and WebMD Global. H.W. is also acting as a paid consultant for AbbVie, Actelion, Biogen, IGES, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis and the Swiss Multiple Sclerosis Society. His research is funded by the German Ministry for Education and Research (BMBF), the Deutsche Forschungsgemeinschaft (DFG), the Else Kr\u00f6ner Fresenius Foundation, the European Union, the Hertie Foundation, the NRW Ministry of Education and Research, the Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children\u2019s Foundation, Biogen, GlaxoSmithKline, Roche Pharma AG and Sanofi-Genzyme. D.A.H., P.A., G.G., W.S., E.F., L.G. and B.C.K. are employees of Novartis. H.G., Y.S., S.G., T.E.N. and C.C.H. are current employees of the Big Data Institute, which received funding from Novartis to collaborate on AI in medicine, including the work presented here. C.B. and S.P.T. are employees of Roche. A.B. received speaker honoraria from Amicus Therapeutics and Biogen. T.E.N. received consulting fees from Perspectum Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}